Dr. Aimee P. Borazanci, MD

Dr. Borazanci practices at Council Oak Comprehensive Healthcare in Tulsa, Oklahoma, part of Muscogee Nation.

Dr. Borazanci's NPI, 1053522847, was assigned on May 24, 2007. Dr. Borazanci graduated from LSU Health Shreveport School of Medicine in 2006. Dr. Borazanci holds Arizona license 47832.

Dr. Borazanci's primary practice is Council Oak Comprehensive Healthcare, at 10109 E 79th St, Tulsa, OK 74133 in Tulsa County. The practice phone is (918) 940-7543.

Dr. Borazanci's primary practice is Council Oak Comprehensive Healthcare in Tulsa, Oklahoma, part of Muscogee Nation. Dr. Borazanci is also affiliated with Good Samaritan Hospital. The medical group on file is Muscogee Nation Department of Health. Dmand AI also links Dr. Borazanci to 1 more home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Borazanci practices, 3 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Borazanci's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Borazanci is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Borazanci's licenses on file in 4 states: Arizona, Indiana, Oklahoma and Louisiana.

Dmand AI lists epilepsy, lower back pain, multiple sclerosis, neuropathy and seizures among the conditions Dr. Borazanci treats.

CMS data shows 255 Medicare services from Dr. Borazanci across 6 procedure codes in 2024, for 167 Medicare patients. Medicare paid $17,980 for them.

CMS counts 167 Medicare patients who saw Dr. Borazanci in 2024. The largest group is 65 to 74, with 69 patients. 69% of them have high cholesterol, and 61% have high blood pressure. 19% are also on Medicaid. Their average risk score is 1.47, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Borazanci's median patient age at 63, with 64% women.

In 2024, Dr. Borazanci wrote 1,761 Medicare Part D claims for 180 patients. 79% of them were for generic drugs. CMS names the drug for 1,554 of them, across 36 drugs with 11 or more claims each, at $2,129,783 in total drug cost. In 2023, CMS named 1,917 claims across 39 drugs.

Dr. Borazanci accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Borazanci as offering telehealth.

Dmand AI links 7 papers to Dr. Borazanci, published from 2014 to 2024. 2014 was the busiest year, with 2. The most frequent topics are Brain, Magnetic Resonance Imaging and Multiple Sclerosis. Dr. Borazanci has published most often in J Neuroimmunol. Dr. Borazanci's most frequent co-authors are John P. Karis, MD and Ping Wang, PTA.

Dmand AI links Dr. Borazanci to 3 clinical trials. Conditions studied include Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive and Multiple Sclerosis, Relapsing-Remitting. Open Payments lists research payments to Dr. Borazanci that name 1 trial.

CMS Open Payments shows 296 general payments to Dr. Borazanci from 8 drug and device companies from 2016 to 2023. Speaker and faculty fees make up the largest share, 69% of the total. Biogen, Inc. paid the most, $100,893. It also lists 1 research payment totaling $388 in 2017, naming 1 clinical trial.

Dr. Borazanci graduated from LSU Health Shreveport School of Medicine in 2006.

Dr. Borazanci is in network with 23 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.